Global Addictions Therapeutics

Addictions Therapeutics Comprehensive Study by Type (Therapy, Medications and Treatment (Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline)), Application (Opioid, Alcohol, Nicotine, Other), End-Use (Treatment Center, Hospitals, Research Organization, Laboratories, Others) Players and Region - Global Market Outlook to 2030

Addictions Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Addictions Therapeutics
Addiction needs personalized treatments that address the symptoms and underlying causes of the disease, as well as the consequences that substance use has on different areas of a person’s life. This contains their ability to socialize, their physical and mental health, and consequences at work, home, school, or with the law. Addiction is a complex disease that can affect many areas of a person’s life. It was estimated that in 2017, 20.7 million Americans needed treatment for substance use disorders; however, only 2.5 million received particular substance use treatment. Drug or alcohol addiction generally cause chronic disorder characterized by occasional relapses, thus, a single treatment might not be enough. The patients might involve a series of treatments for a longer time span which will further increase the need for addiction treatments.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Addictions Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Adial Pharmaceuticals (United States), Indivior PLC (United States), Bausch Health Companies (Canada), Alvogen (United States), Camurus AB (Sweden), Hikma Pharmaceuticals Plc (United Kingdom), Cipla Ltd. (India), Allergan plc (Ireland), Alkermes plc (Ireland), Pfizer Inc. (United States), Orexo AB (Sweden), GlaxoSmithKline plc (United Kingdom), Purdue Pharma L.P (United States), Mallinckrodt Pharmaceuticals (United Kingdom), Reckitt Benckiser (United Kingdom) and Teva Pharmaceuticals (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Forest Laboratories (United States), Indivior PLC (United Kingdom) and Noramco, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Addictions Therapeutics market by Type (Therapy and Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline]), Application (Opioid, Alcohol, Nicotine and Other) and Region.



On the basis of geography, the market of Addictions Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-Use, the sub-segment i.e. Treatment Center will boost the Addictions Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction to Addiction Treatment Drugs with Minimal Side Effects and Growing Demand for Nicotine Addiction Treatments especially Nicotine Gums

Market Growth Drivers:
Assistance to Voluntary Organizations for Prevention of Alcoholism and Drug Abuse and Financial Assistance in the Field of Social Defence

Challenges:
Rising Instances of Misleading Sales Tactics, Deceptive Advertising, and Unethical Marketing Practices and Highly Unregulated Sector of Drug Rehab Vulnerable to many Patients

Restraints:
Numerous Side Effects Associated with the Addiction Treatments Drugs

Opportunities:
Escalating Global Drug or Alcohol Addicted Population and Favorable Government Initiatives related to Addiction Treatment and Drug Development

Market Leaders and their expansionary development strategies
In December 2023, Evrenzo Bioscience, a clinical-stage biopharmaceutical company focused on developing novel treatments for addiction, announced its acquisition of Eupraxia Pharmaceuticals, a company developing an intranasal naloxone spray for opioid overdose reversal. This merger strengthens Evrenzo's pipeline and expands its reach into the critical area of opioid overdose prevention.
In November 2023, Alkermes received FDA approval for Vivitrol Depot, a long-acting injectable form of naltrexone for the treatment of alcohol dependence. Vivitrol Depot offers a new option for patients who struggle with adherence to daily naltrexone tablets.
According to the United States' SAMHSA (Substance Abuse and Mental Health Services Administration), the United States federal government invests billions of dollars every year into combating drug and alcohol addiction. Much of this is spent on law enforcement, but far more is spent on providing health care and treatment. While there are many different programs, the vast majority of this funding comes from Medicare, Medicaid, Veterans Administration (VA) Benefits, and the Affordable Care Act (ACA), better known as Obamacare. While many rehabs accept government funding.

Key Target Audience
Addiction Treatment Providers, Addiction Treatment Drug Manufacturers, Addiction Treatment Drug Distributors and Traders, Healthcare Industry Associations, Government Agencies, Non-Profit Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Therapy
  • Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline]
By Application
  • Opioid
  • Alcohol
  • Nicotine
  • Other
By End-Use
  • Treatment Center
  • Hospitals
  • Research Organization
  • Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Assistance to Voluntary Organizations for Prevention of Alcoholism and Drug Abuse
      • 3.2.2. Financial Assistance in the Field of Social Defence
    • 3.3. Market Challenges
      • 3.3.1. Rising Instances of Misleading Sales Tactics, Deceptive Advertising, and Unethical Marketing Practices
      • 3.3.2. Highly Unregulated Sector of Drug Rehab Vulnerable to many Patients
    • 3.4. Market Trends
      • 3.4.1. Introduction to Addiction Treatment Drugs with Minimal Side Effects
      • 3.4.2. Growing Demand for Nicotine Addiction Treatments especially Nicotine Gums
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Addictions Therapeutics, by Type, Application, End-Use and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Addictions Therapeutics (Value)
      • 5.2.1. Global Addictions Therapeutics by: Type (Value)
        • 5.2.1.1. Therapy
        • 5.2.1.2. Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline]
      • 5.2.2. Global Addictions Therapeutics by: Application (Value)
        • 5.2.2.1. Opioid
        • 5.2.2.2. Alcohol
        • 5.2.2.3. Nicotine
        • 5.2.2.4. Other
      • 5.2.3. Global Addictions Therapeutics by: End-Use (Value)
        • 5.2.3.1. Treatment Center
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Research Organization
        • 5.2.3.4. Laboratories
        • 5.2.3.5. Others
      • 5.2.4. Global Addictions Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Addictions Therapeutics (Price)
      • 5.3.1. Global Addictions Therapeutics by: Type (Price)
  • 6. Addictions Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Adial Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Indivior PLC (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bausch Health Companies (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alvogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Camurus AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals Plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alkermes plc (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Orexo AB (Sweden)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GlaxoSmithKline plc (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Purdue Pharma L.P (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Reckitt Benckiser (United Kingdom)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Teva Pharmaceuticals (Israel)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Addictions Therapeutics Sale, by Type, Application, End-Use and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Addictions Therapeutics (Value)
      • 7.2.1. Global Addictions Therapeutics by: Type (Value)
        • 7.2.1.1. Therapy
        • 7.2.1.2. Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline]
      • 7.2.2. Global Addictions Therapeutics by: Application (Value)
        • 7.2.2.1. Opioid
        • 7.2.2.2. Alcohol
        • 7.2.2.3. Nicotine
        • 7.2.2.4. Other
      • 7.2.3. Global Addictions Therapeutics by: End-Use (Value)
        • 7.2.3.1. Treatment Center
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Research Organization
        • 7.2.3.4. Laboratories
        • 7.2.3.5. Others
      • 7.2.4. Global Addictions Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Addictions Therapeutics (Price)
      • 7.3.1. Global Addictions Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Addictions Therapeutics: by Type(USD Million)
  • Table 2. Addictions Therapeutics Therapy , by Region USD Million (2018-2023)
  • Table 3. Addictions Therapeutics Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline] , by Region USD Million (2018-2023)
  • Table 4. Addictions Therapeutics: by Application(USD Million)
  • Table 5. Addictions Therapeutics Opioid , by Region USD Million (2018-2023)
  • Table 6. Addictions Therapeutics Alcohol , by Region USD Million (2018-2023)
  • Table 7. Addictions Therapeutics Nicotine , by Region USD Million (2018-2023)
  • Table 8. Addictions Therapeutics Other , by Region USD Million (2018-2023)
  • Table 9. Addictions Therapeutics: by End-Use(USD Million)
  • Table 10. Addictions Therapeutics Treatment Center , by Region USD Million (2018-2023)
  • Table 11. Addictions Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 12. Addictions Therapeutics Research Organization , by Region USD Million (2018-2023)
  • Table 13. Addictions Therapeutics Laboratories , by Region USD Million (2018-2023)
  • Table 14. Addictions Therapeutics Others , by Region USD Million (2018-2023)
  • Table 15. South America Addictions Therapeutics, by Country USD Million (2018-2023)
  • Table 16. South America Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 17. South America Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 18. South America Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 19. Brazil Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 20. Brazil Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 21. Brazil Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 22. Argentina Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 23. Argentina Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 24. Argentina Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 25. Rest of South America Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 27. Rest of South America Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 28. Asia Pacific Addictions Therapeutics, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 31. Asia Pacific Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 32. China Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 33. China Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 34. China Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 35. Japan Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 36. Japan Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 37. Japan Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 38. India Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 39. India Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 40. India Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 41. South Korea Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 42. South Korea Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 43. South Korea Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 44. Taiwan Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 45. Taiwan Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 46. Taiwan Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 47. Australia Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 48. Australia Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 49. Australia Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 53. Europe Addictions Therapeutics, by Country USD Million (2018-2023)
  • Table 54. Europe Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 55. Europe Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 56. Europe Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 57. Germany Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 58. Germany Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 59. Germany Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 60. France Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 61. France Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 62. France Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 63. Italy Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 64. Italy Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 65. Italy Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 66. United Kingdom Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 68. United Kingdom Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 69. Netherlands Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 70. Netherlands Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 71. Netherlands Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 72. Rest of Europe Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 74. Rest of Europe Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 75. MEA Addictions Therapeutics, by Country USD Million (2018-2023)
  • Table 76. MEA Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 77. MEA Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 78. MEA Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 79. Middle East Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 80. Middle East Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 81. Middle East Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 82. Africa Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 83. Africa Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 84. Africa Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 85. North America Addictions Therapeutics, by Country USD Million (2018-2023)
  • Table 86. North America Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 87. North America Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 88. North America Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 89. United States Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 90. United States Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 91. United States Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 92. Canada Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 93. Canada Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 94. Canada Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 95. Mexico Addictions Therapeutics, by Type USD Million (2018-2023)
  • Table 96. Mexico Addictions Therapeutics, by Application USD Million (2018-2023)
  • Table 97. Mexico Addictions Therapeutics, by End-Use USD Million (2018-2023)
  • Table 98. Addictions Therapeutics: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Addictions Therapeutics: by Type(USD Million)
  • Table 116. Addictions Therapeutics Therapy , by Region USD Million (2025-2030)
  • Table 117. Addictions Therapeutics Medications and Treatment [Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline] , by Region USD Million (2025-2030)
  • Table 118. Addictions Therapeutics: by Application(USD Million)
  • Table 119. Addictions Therapeutics Opioid , by Region USD Million (2025-2030)
  • Table 120. Addictions Therapeutics Alcohol , by Region USD Million (2025-2030)
  • Table 121. Addictions Therapeutics Nicotine , by Region USD Million (2025-2030)
  • Table 122. Addictions Therapeutics Other , by Region USD Million (2025-2030)
  • Table 123. Addictions Therapeutics: by End-Use(USD Million)
  • Table 124. Addictions Therapeutics Treatment Center , by Region USD Million (2025-2030)
  • Table 125. Addictions Therapeutics Hospitals , by Region USD Million (2025-2030)
  • Table 126. Addictions Therapeutics Research Organization , by Region USD Million (2025-2030)
  • Table 127. Addictions Therapeutics Laboratories , by Region USD Million (2025-2030)
  • Table 128. Addictions Therapeutics Others , by Region USD Million (2025-2030)
  • Table 129. South America Addictions Therapeutics, by Country USD Million (2025-2030)
  • Table 130. South America Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 131. South America Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 132. South America Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 133. Brazil Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 134. Brazil Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 135. Brazil Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 136. Argentina Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 137. Argentina Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 138. Argentina Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 139. Rest of South America Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 140. Rest of South America Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 141. Rest of South America Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 142. Asia Pacific Addictions Therapeutics, by Country USD Million (2025-2030)
  • Table 143. Asia Pacific Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 144. Asia Pacific Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 145. Asia Pacific Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 146. China Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 147. China Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 148. China Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 149. Japan Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 150. Japan Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 151. Japan Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 152. India Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 153. India Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 154. India Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 155. South Korea Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 156. South Korea Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 157. South Korea Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 158. Taiwan Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 159. Taiwan Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 160. Taiwan Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 161. Australia Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 162. Australia Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 163. Australia Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 164. Rest of Asia-Pacific Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 165. Rest of Asia-Pacific Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 166. Rest of Asia-Pacific Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 167. Europe Addictions Therapeutics, by Country USD Million (2025-2030)
  • Table 168. Europe Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 169. Europe Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 170. Europe Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 171. Germany Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 172. Germany Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 173. Germany Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 174. France Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 175. France Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 176. France Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 177. Italy Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 178. Italy Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 179. Italy Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 180. United Kingdom Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 181. United Kingdom Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 182. United Kingdom Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 183. Netherlands Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 184. Netherlands Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 185. Netherlands Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 186. Rest of Europe Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 187. Rest of Europe Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 188. Rest of Europe Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 189. MEA Addictions Therapeutics, by Country USD Million (2025-2030)
  • Table 190. MEA Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 191. MEA Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 192. MEA Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 193. Middle East Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 194. Middle East Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 195. Middle East Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 196. Africa Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 197. Africa Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 198. Africa Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 199. North America Addictions Therapeutics, by Country USD Million (2025-2030)
  • Table 200. North America Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 201. North America Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 202. North America Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 203. United States Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 204. United States Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 205. United States Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 206. Canada Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 207. Canada Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 208. Canada Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 209. Mexico Addictions Therapeutics, by Type USD Million (2025-2030)
  • Table 210. Mexico Addictions Therapeutics, by Application USD Million (2025-2030)
  • Table 211. Mexico Addictions Therapeutics, by End-Use USD Million (2025-2030)
  • Table 212. Addictions Therapeutics: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Addictions Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Addictions Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Addictions Therapeutics: by End-Use USD Million (2018-2023)
  • Figure 7. South America Addictions Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Addictions Therapeutics Share (%), by Country
  • Figure 9. Europe Addictions Therapeutics Share (%), by Country
  • Figure 10. MEA Addictions Therapeutics Share (%), by Country
  • Figure 11. North America Addictions Therapeutics Share (%), by Country
  • Figure 12. Global Addictions Therapeutics: by Type USD/Units (2018-2023)
  • Figure 13. Global Addictions Therapeutics share by Players 2023 (%)
  • Figure 14. Global Addictions Therapeutics share by Players (Top 3) 2023(%)
  • Figure 15. Global Addictions Therapeutics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Adial Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Adial Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 19. Indivior PLC (United States) Revenue, Net Income and Gross profit
  • Figure 20. Indivior PLC (United States) Revenue: by Geography 2023
  • Figure 21. Bausch Health Companies (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Bausch Health Companies (Canada) Revenue: by Geography 2023
  • Figure 23. Alvogen (United States) Revenue, Net Income and Gross profit
  • Figure 24. Alvogen (United States) Revenue: by Geography 2023
  • Figure 25. Camurus AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 26. Camurus AB (Sweden) Revenue: by Geography 2023
  • Figure 27. Hikma Pharmaceuticals Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Hikma Pharmaceuticals Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Cipla Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla Ltd. (India) Revenue: by Geography 2023
  • Figure 31. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Allergan plc (Ireland) Revenue: by Geography 2023
  • Figure 33. Alkermes plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Alkermes plc (Ireland) Revenue: by Geography 2023
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Orexo AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 38. Orexo AB (Sweden) Revenue: by Geography 2023
  • Figure 39. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Purdue Pharma L.P (United States) Revenue, Net Income and Gross profit
  • Figure 42. Purdue Pharma L.P (United States) Revenue: by Geography 2023
  • Figure 43. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 45. Reckitt Benckiser (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. Reckitt Benckiser (United Kingdom) Revenue: by Geography 2023
  • Figure 47. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 48. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 49. Global Addictions Therapeutics: by Type USD Million (2025-2030)
  • Figure 50. Global Addictions Therapeutics: by Application USD Million (2025-2030)
  • Figure 51. Global Addictions Therapeutics: by End-Use USD Million (2025-2030)
  • Figure 52. South America Addictions Therapeutics Share (%), by Country
  • Figure 53. Asia Pacific Addictions Therapeutics Share (%), by Country
  • Figure 54. Europe Addictions Therapeutics Share (%), by Country
  • Figure 55. MEA Addictions Therapeutics Share (%), by Country
  • Figure 56. North America Addictions Therapeutics Share (%), by Country
  • Figure 57. Global Addictions Therapeutics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Adial Pharmaceuticals (United States)
  • Indivior PLC (United States)
  • Bausch Health Companies (Canada)
  • Alvogen (United States)
  • Camurus AB (Sweden)
  • Hikma Pharmaceuticals Plc (United Kingdom)
  • Cipla Ltd. (India)
  • Allergan plc (Ireland)
  • Alkermes plc (Ireland)
  • Pfizer Inc. (United States)
  • Orexo AB (Sweden)
  • GlaxoSmithKline plc (United Kingdom)
  • Purdue Pharma L.P (United States)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • Reckitt Benckiser (United Kingdom)
  • Teva Pharmaceuticals (Israel)
Additional players considered in the study are as follows:
Forest Laboratories (United States) , Indivior PLC (United Kingdom) , Noramco, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 217 Pages 87 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Addictions Therapeutics Quantitative research analysis
Global Addictions Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Adial Pharmaceuticals (United States), Indivior PLC (United States), Bausch Health Companies (Canada), Alvogen (United States), Camurus AB (Sweden), Hikma Pharmaceuticals Plc (United Kingdom), Cipla Ltd. (India), Allergan plc (Ireland), Alkermes plc (Ireland), Pfizer Inc. (United States), Orexo AB (Sweden), GlaxoSmithKline plc (United Kingdom), Purdue Pharma L.P (United States), Mallinckrodt Pharmaceuticals (United Kingdom), Reckitt Benckiser (United Kingdom) and Teva Pharmaceuticals (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Introduction to Addiction Treatment Drugs with Minimal Side Effects " is seen as one of major influencing trends for Addictions Therapeutics Market during projected period 2023-2030.
The Addictions Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Addictions Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Hyperhidrosis Treatment Comprehensive Study by Type (Antiperspirants, Iontophoresis, Botulinum toxin injections, Prescription cloth wipes, Prescription medicine, Surgery), Application (Hospitals, Der...
$ 3650
Allergy Diagnostics And Treatment Comprehensive Study by Application (Diagnostic Laboratories, Hospital-Based Laboratories, Academic Research Institutes, Other End Users), Tests Type (Specific IgE te...
$ 3750
Monoclonal Antibodies Drug Comprehensive Study by Application (Oncology, Autoimmune, Inflammatory Diseases, Respiratory Diseases, Ophthalmology, Others), Origin (Murine Antibodies, Human Antibodies, ...
$ 3650
Medical Skincare Comprehensive Study by Type (Cleansers, Toners, Scrubs & Masks, Serums, Moisturizers, Eye Creams, SPF, Others), Application (Acne, Anti-Aging, Brightening, Sensitive Skin, Dry Skin, ...
$ 3750
Weight Loss Therapeutics Comprehensive Study by Therapy (Intensive Behavioural Therapy, Self-Monitoring Therapy), End Users (Hospitals, Therapy Clinics, Pharmaceuticals Organization), Distribution Ch...
$ 3650
Genitourinary System Treatment Comprehensive Study by Type (OTC, Rx Drugs), Application (Hospital, Clinics, Ambulatory Surgical Centers), Drugs (Hormonal Therapy, Impotence Agents, Uterine Relaxants,...
$ 3750